Vir Biotechnology (VIR) News Today $10.11 +0.06 (+0.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $34.83 Average PT from BrokeragesJanuary 18 at 3:59 AM | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Trading Down 10.4% - What's Next?Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Should You Sell?January 15, 2025 | marketbeat.comVir Biotechnology Receives Buy Rating: Promising TCE Programs and Strategic Focus Boost Growth OutlookJanuary 15, 2025 | markets.businessinsider.comQ1 Earnings Forecast for VIR Issued By Leerink PartnrsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings ofJanuary 15, 2025 | marketbeat.comJPMorgan Chase & Co. Has $8.14 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)JPMorgan Chase & Co. cut its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 13.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,086,327 shares of the company's stock after selling 168,971 sharJanuary 15, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for VIR Q2 Earnings?January 15, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for VIR Q2 EarningsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings peJanuary 14, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Here's WhyVir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Time to Sell?January 13, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have iJanuary 13, 2025 | marketbeat.comLeerink Partners Issues Positive Forecast for Vir Biotechnology (NASDAQ:VIR) Stock PriceLeerink Partners lifted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday.January 13, 2025 | marketbeat.comNordea Investment Management AB Has $1 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Nordea Investment Management AB trimmed its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 67.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 136,487 shares of the company's sJanuary 13, 2025 | marketbeat.comVir Biotechnology's (VIR) "Buy" Rating Reaffirmed at HC WainwrightJanuary 13, 2025 | americanbankingnews.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Vir Biotechnology (NASDAQ:VIR) StockJanuary 12, 2025 | americanbankingnews.comVir Biotechnology: Buy Rating Supported by Promising TCE Programs and Strategic PartnershipsJanuary 11, 2025 | markets.businessinsider.comMorgan Stanley Doubles Vir Biotechnology Price Forecast - Here's WhyJanuary 10, 2025 | benzinga.comVir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday.January 10, 2025 | marketbeat.comVir Biotechnology upgraded to Overweight from Equal Weight at Morgan StanleyJanuary 10, 2025 | markets.businessinsider.comVir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%January 10, 2025 | finance.yahoo.comMorgan Stanley Upgrades Vir Biotechnology (VIR)January 10, 2025 | msn.comStock Traders Purchase High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR)January 10, 2025 | americanbankingnews.comMorgan Stanley Sees 67% Upside Potential for Vir Biotechnology StockJanuary 9, 2025 | finance.yahoo.comVir Biotechnology: A Rocket Off Phase 1 DataJanuary 9, 2025 | seekingalpha.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $14.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their target price on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research report on Thursday.January 9, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Morgan StanleyMorgan Stanley upgraded shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $10.00 to $20.00 in a report on Thursday.January 9, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Time to Buy?Vir Biotechnology (NASDAQ:VIR) Reaches New 1-Year High - Time to Buy?January 9, 2025 | marketbeat.comVir Biotechnology’s Early Promise in Clinical Trials Warrants Hold Rating Amid UncertaintiesJanuary 9, 2025 | markets.businessinsider.comVir Biotechnology’s Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term UncertaintiesJanuary 9, 2025 | markets.businessinsider.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,960 Shares of StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki L. Sato sold 10,960 shares of the firm's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares of the company's stock, valued at $16,431,135.32. This represents a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 8, 2025 | marketbeat.comVir Biotechnology stock soars on promising trial dataJanuary 8, 2025 | au.investing.comVir Biotechnology price target lowered to $14 from $15 at BofAJanuary 8, 2025 | finance.yahoo.comVir Biotech Shares Rise on Positive Data for Cancer TreatmentsJanuary 8, 2025 | marketwatch.comVir Biotechnology’s Promising TCE Oncology Assets Earn Buy Rating from Joseph StringerJanuary 8, 2025 | markets.businessinsider.comVir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in CancerJanuary 8, 2025 | msn.comVir Biotechnology Catapults 64% On Promising Results In Cancer TreatmentJanuary 8, 2025 | msn.comVir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's WhyJanuary 8, 2025 | benzinga.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next?Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - Here's What HappenedJanuary 8, 2025 | marketbeat.comInvestors Purchase High Volume of Call Options on Vir Biotechnology (NASDAQ:VIR)Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock traders bought 6,929 call options on the stock. This represents an increase of approximately 933% compared to the average daily volume of 671 call options.January 8, 2025 | marketbeat.comVir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPCJanuary 8, 2025 | businesswire.comVir Biotechnology (NASDAQ:VIR) Trading 7.1% Higher - What's Next?Vir Biotechnology (NASDAQ:VIR) Stock Price Up 7.1% - Here's What HappenedJanuary 6, 2025 | marketbeat.comFDA revokes EUAs for some antibody treatments for COVID-19December 23, 2024 | markets.businessinsider.comState Street Corp Has $42.14 Million Position in Vir Biotechnology, Inc. (NASDAQ:VIR)State Street Corp grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 10.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 5,625,533 shares of the company's stock after buying an additional 530,645 shares during the period. State Street CDecember 21, 2024 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd cut its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 78.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,455 shares of the company's stock after selDecember 20, 2024 | marketbeat.comVir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | businesswire.comCautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial OutlookDecember 18, 2024 | markets.businessinsider.comVir receives FDA, EMA designations for tobevibart and elebsiranDecember 13, 2024 | markets.businessinsider.comVir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In JanuaryDecember 13, 2024 | seekingalpha.comVir gets FDA breakthrough therapy status for two drugsDecember 12, 2024 | msn.comVir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaDecember 12, 2024 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 13.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,134,276 shares of the company's stock after purchasing an aDecember 11, 2024 | marketbeat.comVir has positive readthrough from Janux data, says Morgan StanleyDecember 3, 2024 | markets.businessinsider.com Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼1.030.44▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼125▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYTK News NUVL News GRFS News TGTX News AXSM News KRYS News VRNA News OGN News SRRK News ALVO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIR Stock Alerts